[{"id":"fe022431-48d1-445d-8c8d-2321aa360be4","acronym":"","url":"https://clinicaltrials.gov/study/NCT05828082","created_at":"2023-04-25T14:03:34.885Z","updated_at":"2024-07-02T16:34:26.664Z","phase":"Phase 2","brief_title":"Testing the Effect of M1774 on Hard-to-Treat Refractory SPOP-mutant Prostate Cancer","source_id_and_acronym":"NCT05828082","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" SPOP • RAC1 • FDFT1 • MVD","pipe":" | ","alterations":" SPOP mutation","tags":["SPOP • RAC1 • FDFT1 • MVD"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e SPOP mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e tuvusertib (M1774)"],"overall_status":"Recruiting","enrollment":" Enrollment 20","initiation":"Initiation: 10/16/2023","start_date":" 10/16/2023","primary_txt":" Primary completion: 04/25/2025","primary_completion_date":" 04/25/2025","study_txt":" Completion: 04/25/2025","study_completion_date":" 04/25/2025","last_update_posted":"2024-06-12"},{"id":"f180fa4a-86d7-4c90-bf6f-101d2893b440","acronym":"","url":"https://clinicaltrials.gov/study/NCT05689021","created_at":"2023-01-18T14:59:57.536Z","updated_at":"2024-07-02T16:35:04.068Z","phase":"Phase 2","brief_title":"CJNJ-67652000 and Prednisone for Treatment of Metastatic Castration-Resistant Prostate Cancer and SPOP Gene Mutations","source_id_and_acronym":"NCT05689021","lead_sponsor":"Mayo Clinic","biomarkers":" SPOP","pipe":" | ","alterations":" SPOP mutation","tags":["SPOP"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e SPOP mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Zejula (niraparib) • abiraterone acetate • Akeega (abiraterone/niraparib)"],"overall_status":"Recruiting","enrollment":" Enrollment 30","initiation":"Initiation: 03/05/2024","start_date":" 03/05/2024","primary_txt":" Primary completion: 09/01/2024","primary_completion_date":" 09/01/2024","study_txt":" Completion: 09/01/2025","study_completion_date":" 09/01/2025","last_update_posted":"2024-05-13"}]